- Home
- TBI vs ENVB Comparison
TBI vs ENVB Comparison
Compare TBI & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TBI | ENVB |
|---|---|---|
| Founded | 1985 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.9M | 3.0M |
| IPO Year | 1996 | N/A |
Fundamental Metrics
Financial Performance| Metric | TBI | ENVB |
|---|---|---|
| Price | $4.95 | $5.55 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $6.00 | ★ $120.00 |
| AVG Volume (30 Days) | 156.4K | ★ 1.9M |
| Earning Date | 11-03-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,583,772,000.00 | N/A |
| Revenue This Year | $3.80 | N/A |
| Revenue Next Year | $5.04 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.45 | $4.88 |
| 52 Week High | $9.05 | $96.30 |
Technical Indicators
Market Signals| Indicator | TBI | ENVB |
|---|---|---|
| Relative Strength Index (RSI) | 48.64 | 48.80 |
| Support Level | $4.74 | $5.05 |
| Resistance Level | $5.04 | $13.25 |
| Average True Range (ATR) | 0.22 | 1.20 |
| MACD | 0.03 | -0.10 |
| Stochastic Oscillator | 50.57 | 4.63 |
Price Performance
Historical ComparisonAbout TBI TrueBlue Inc.
TrueBlue Inc is a provider of staffing and workforce management solutions. Its reportable segments include PeopleReady offers industrial staffing services. PeopleManagement offers contingent and productivity-based on-site industrial staffing services and PeopleScout offers recruitment process outsourcing, talent advisory services, and managed service provider services. It generates maximum revenue from the PeopleReady segment.
About ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.